Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.

Autor: Tomita Y; Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan., Hansson E; Pharmetheus AB, Uppsala, Sweden., Mazuir F; Poxel SA, Lyon, France., Wellhagen GJ; Pharmetheus AB, Uppsala, Sweden., Ooi QX; Pharmetheus AB, Uppsala, Sweden., Mezzalana E; Pharmetheus AB, Uppsala, Sweden., Kitamura A; Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan., Nemoto D; Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan., Bolze S; Poxel SA, Lyon, France.
Jazyk: angličtina
Zdroj: Clinical and translational science [Clin Transl Sci] 2022 Apr; Vol. 15 (4), pp. 1014-1026. Date of Electronic Publication: 2022 Jan 17.
DOI: 10.1111/cts.13221
Abstrakt: Imeglimin is an orally administered first-in-class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing regimen for Japanese patients with T2DM and chronic kidney disease (CKD). Imeglimin plasma concentrations in Japanese and Western healthy volunteers, and patients with T2DM, including patients with mild to severe CKD with an estimated glomerular filtration rate (eGFR) greater than 14 ml/min/1.73 m 2 were included in a population PK analysis. PK simulations were conducted using a population PK model, and the area under concentration-time curve (AUC) was extrapolated with power regression analysis to lower eGFR. The influence of eGFR, weight, and age on apparent clearance and of dose on relative bioavailability were quantified by population PK analysis. Simulations and extrapolation revealed that the recommended dosing regimen based on the AUC was 500 mg twice daily (b.i.d.) for patients with eGFR 15-45 ml/min/1.73 m 2 , and 500 mg with a longer dosing interval was suggested for those with eGFR less than 15. Simulations revealed that differences in plasma AUCs between Japanese and Western patients at the same dose were mainly driven by a difference in the eGFR and that the plasma AUC after 1000 and 1500 mg b.i.d. in Japanese and Western patients, respectively, was comparable in the phase IIb studies. These results indicate suitable dosages of imeglimin in the clinical setting of T2DM with renal impairment.
(© 2021 Sumitomo Dainippon Pharma Co., Ltd and Poxel SA. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz: